Abstract
In the last decade, there has been enormous progress in our understanding of Frontotemporal Lobar Degeneration (FTLD). Published clinicopathological series have clearly demonstrated an overlap between the clinical syndromes subsumed under the term frontotemporal dementia and the Progressive Supranuclear Palsy (PSP), and the Corticobasal Degeneration (CBD) syndrome. From a neuropathological point of view, two broad pathological subdivisions of FTLD are currently recognized: a) tau-positive pathology due to the accumulation of various forms of the microtubule-associated protein tau, that encompasses FTLD with Pick bodies, PSP and CBD, and b) tau-negative pathology, mainly characterised by ubiquitin/TDP-43-immunoreactive inclusions and in some cases due to Progranulin mutations. Several biological markers in cerebrospinal fluid and in blood have been evaluated to identify monogenic forms of FTLD and to differentiate either FTLD spectrum disorders or FTLD from other neurodegenerative disorders. The proposed biomarkers are primarily related to the mechanisms underlying the accumulation of the abnormal proteins in FTLD such as Tau, TDP-43 and Progranulin. These biomarkers may support the accurate diagnosis of the specific diseases causing FTLD, can be useful in assessing efficacy during pharmacological trials, and may help in identifying new molecular targets for treatment approaches. In this review, we summarise the most recent findings on biological markers and their usefulness in clinical practice for the diagnosis and management of FTLD.
Keywords: Frontotemporal Lobar degeneration, frontotemporal dementia, progressive supranuclear palsy, corticobasal degeneration syndrome, biomarkers, progranulin, tau, cerebrospinal fluid
Current Medicinal Chemistry
Title: New Insights into Biological Markers of Frontotemporal Lobar Degeneration Spectrum
Volume: 17 Issue: 10
Author(s): Barbara Borroni, Antonella Alberici, Silvana Archetti, Enrico Magnani, Monica Di Luca and Alessandro Padovani
Affiliation:
Keywords: Frontotemporal Lobar degeneration, frontotemporal dementia, progressive supranuclear palsy, corticobasal degeneration syndrome, biomarkers, progranulin, tau, cerebrospinal fluid
Abstract: In the last decade, there has been enormous progress in our understanding of Frontotemporal Lobar Degeneration (FTLD). Published clinicopathological series have clearly demonstrated an overlap between the clinical syndromes subsumed under the term frontotemporal dementia and the Progressive Supranuclear Palsy (PSP), and the Corticobasal Degeneration (CBD) syndrome. From a neuropathological point of view, two broad pathological subdivisions of FTLD are currently recognized: a) tau-positive pathology due to the accumulation of various forms of the microtubule-associated protein tau, that encompasses FTLD with Pick bodies, PSP and CBD, and b) tau-negative pathology, mainly characterised by ubiquitin/TDP-43-immunoreactive inclusions and in some cases due to Progranulin mutations. Several biological markers in cerebrospinal fluid and in blood have been evaluated to identify monogenic forms of FTLD and to differentiate either FTLD spectrum disorders or FTLD from other neurodegenerative disorders. The proposed biomarkers are primarily related to the mechanisms underlying the accumulation of the abnormal proteins in FTLD such as Tau, TDP-43 and Progranulin. These biomarkers may support the accurate diagnosis of the specific diseases causing FTLD, can be useful in assessing efficacy during pharmacological trials, and may help in identifying new molecular targets for treatment approaches. In this review, we summarise the most recent findings on biological markers and their usefulness in clinical practice for the diagnosis and management of FTLD.
Export Options
About this article
Cite this article as:
Borroni Barbara, Alberici Antonella, Archetti Silvana, Magnani Enrico, Luca Di Monica and Padovani Alessandro, New Insights into Biological Markers of Frontotemporal Lobar Degeneration Spectrum, Current Medicinal Chemistry 2010; 17 (10) . https://dx.doi.org/10.2174/092986710790820651
DOI https://dx.doi.org/10.2174/092986710790820651 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Lipases in Medicine: An Overview
Mini-Reviews in Medicinal Chemistry Ethnic and Geographical Differences in Ischaemic Stroke Among Young Adults
Current Vascular Pharmacology Beneficial Neurobiological Effects of Melatonin Under Conditions of Increased Oxidative Stress
Current Medicinal Chemistry - Central Nervous System Agents K114 Inhibits A-beta Aggregation and Inflammation In Vitro and In Vivo in AD/Tg Mice
Current Alzheimer Research Development of Bivalent Acetylcholinesterase Inhibitors as Potential Therapeutic Drugs for Alzheimers Disease
Current Pharmaceutical Design Ceramide Involvement in Apoptosis and Apoptotic Diseases
Mini-Reviews in Medicinal Chemistry Advanced Glycation End Products: A Link Between Periodontitis and Diabetes Mellitus?
Current Diabetes Reviews Increased Acetylation of Histone H4 at Lysine 12 (H4K12) in Monocytes of Transgenic Alzheimer’s Mice and in Human Patients
Current Alzheimer Research Cardiovascular and Systemic Risk in Nonalcoholic Fatty Liver Disease - Atherosclerosis as a Major Player in the Natural Course of NAFLD
Current Pharmaceutical Design Drugs for the Treatment of Hypercholesterolemia and their Benefits Beyond Cholesterol Lowering to Prevent Vascular Disease
Vascular Disease Prevention (Discontinued) Role of Amylin and its Receptors in Neurodegeneration
Current Protein & Peptide Science The Role of Autophagy in the Pathogenesis of Ischemic Stroke
Current Neuropharmacology New Perspectives of Alzheimer Disease Diagnosis – the Most Popular and Future Methods
Medicinal Chemistry Protein Misfolding in Disease: Cause or Response?
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Effects of Exercise and Ferulic Acid on Alpha Synuclein and Neuroprotective Heat Shock Protein 70 in An Experimental Model of Parkinsonism Disease
CNS & Neurological Disorders - Drug Targets Investigating Serotonergic Function Using Positron Emission Tomography: Overview and Recent Findings
Current Pharmaceutical Design Possible Hypoxia Signaling Induced Alteration of Glucose Homeostasis in Rats Exposed to Chronic Intermittent Hypoxia - Role of Antioxidant (Vitamin C) and Ca2+ Channel Blocker (Cilnidipine)
Current Signal Transduction Therapy Assessment of Acute Coronary Syndromes: Focus on Novel Biomarkers
Current Medicinal Chemistry Targeting the Role of Lipoprotein (a) in Stroke
Cardiovascular & Hematological Disorders-Drug Targets Stroke in Women
Recent Patents on Cardiovascular Drug Discovery